The price of Dawnzera is not publicly disclosed. Dawnzera (idarucizumab) is an antidote used to reverse the effects of the anticoagulant pradaxa [1]. The cost of idarucizumab can vary significantly depending on factors such as the prescribing institution, insurance coverage, and geographic location [2].
How much does idarucizumab cost?
The cost of idarucizumab (the active ingredient in Dawnzera) can be substantial, often ranging from several thousand dollars per dose [2]. For instance, some sources have indicated prices around $2,000 to $4,000 per vial, but these figures are not official and can fluctuate [2].
What is the recommended dosage for idarucizumab?
The recommended dose of idarucizumab is a single intravenous administration of 5 grams [1]. This dose is delivered as two 2.5-gram bolus injections [1].
What is idarucizumab used for?
Idarucizumab is specifically indicated for use in patients treated with pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is needed due to life-threatening or uncontrollable bleeding [1]. Pradaxa is a direct thrombin inhibitor used to prevent blood clots [3].
What are the risks associated with idarucizumab?
The primary risk noted with idarucizumab is an increased risk of thrombotic events due to the reversal of dabigatran's anticoagulant effect [1]. Patients who have experienced a thrombotic event while on dabigatran may be at higher risk [1]. Other potential side effects, though less common, can include pneumonia, delirium, and urinary tract infections [1].
Who manufactures Dawnzera?
Dawnzera is manufactured by Boehringer Ingelheim [1].
What is the clinical efficacy of idarucizumab?
Clinical trials have demonstrated that idarucizumab rapidly and effectively reverses the anticoagulant effect of dabigatran [1]. Studies showed a significant reduction in the medianenediamine concentration and a normalization of the activated partial thromboplastin time (aPTT) within minutes of administration [1].
How does idarucizumab work?
Idarucizumab is a monoclonal antibody fragment that binds to dabigatran with high affinity, neutralizing its anticoagulant activity [1]. It acts as a specific antidote, unlike non-specific reversal agents [1].
When was idarucizumab approved?
Idarucizumab received U.S. Food and Drug Administration (FDA) approval in October 2015 [4].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208919s000lbl.pdf
[2] https://www.goodrx.com/idarucizumab
[3] https://www.nhs.uk/medicines/dabigatran/
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-drug-safety-communication-idarucizumab-praxbind